Herting E, Möller O, Schiffmann J H, Robertson B
Acta Paediatr. 2002;91(11):1174-8. doi: 10.1080/080352502320777397.
Pneumonia in childhood may be associated with surfactant dysfunction and severe acute respiratory distress syndrome (ARDS). The aim of this study was to investigate the effects of surfactant treatment on oxygenation in 8 infants (age range: 1 mo to 13 y) with severe respiratory failure owing to viral, bacterial or Pneumocystis Carinii pneumonia.
Instillation of a modified porcine surfactant (Curosurf) improved gas exchange immediately. Median paO2/FiO2 increased from 66 to 140 mmHg (8.8-18.7 kPa; p < 0.01) within 1 h of surfactant treatment. Seven of the 8 patients received multiple surfactant doses. Four patients (50%) died 3-62 d after surfactant treatment. However, 6 patients (75%) were immunodeficient, so that the observed mortality rate was mainly due to the underlying disease.
Surfactant dysfunction probably plays a role in the pathophysiology of severe paediatric ARDS triggered by pneumonia, as it was found that surfactant instillation rapidly improved gas exchange in the majority of the affected infants in our study. Larger randomized controlled studies are necessary to evaluate the effects of surfactant treatment on morbidity and mortality.
儿童肺炎可能与表面活性剂功能障碍及严重急性呼吸窘迫综合征(ARDS)有关。本研究旨在探讨表面活性剂治疗对8例因病毒、细菌或卡氏肺孢子虫肺炎导致严重呼吸衰竭的婴儿(年龄范围:1个月至13岁)氧合的影响。
滴注改良猪肺表面活性剂(固尔苏)可立即改善气体交换。在表面活性剂治疗后1小时内,动脉血氧分压/吸入氧分数值(PaO2/FiO2)中位数从66 mmHg升至140 mmHg(8.8 - 18.7 kPa;p < 0.01)。8例患者中有7例接受了多次表面活性剂剂量治疗。4例患者(50%)在表面活性剂治疗后3 - 62天死亡。然而,6例患者(75%)存在免疫缺陷,因此观察到的死亡率主要归因于基础疾病。
表面活性剂功能障碍可能在肺炎引发的严重儿童ARDS病理生理过程中起作用,因为在我们的研究中发现,对大多数受影响婴儿滴注表面活性剂可迅速改善气体交换。需要开展更大规模的随机对照研究来评估表面活性剂治疗对发病率和死亡率的影响。